Medical cannabis

From WikiMD's Wellness Encyclopedia

(Redirected from Canasol)

Cannabis sativa L. (marijuana; hemp) used medicinally


Template:Other uses of

"Medical marijuana" redirects here. For the company, see Medical Marijuana, Inc.

Template:Cs1 config



Part of a series on
Cannabis
Cannabis
Chemistry
  • Semi-synthetic cannabinoids
Pharmacology
Consumption
Economics
Effects
Forms
Law
Variants
  • Genus
  • Species
Related

Medical cannabis, medicinal cannabis or medical marijuana (MMJ) refers to cannabis products and cannabinoid molecules that are prescribed by physicians for their patients.[1][2][3][4] The use of cannabis as medicine has a long history, but has not been as rigorously tested as other medicinal plants due to legal and governmental restrictions, resulting in limited clinical research to define the safety and efficacy of using cannabis to treat diseases.[5]

Preliminary evidence has indicated that cannabis might reduce nausea and vomiting during chemotherapy and reduce chronic pain and muscle spasms.[6][7] Regarding non-inhaled cannabis or cannabinoids, a 2021 review found that it provided little relief against chronic pain and sleep disturbance, and caused several transient adverse effects, such as cognitive impairment, nausea, and drowsiness.[8]

Short-term use increases the risk of minor and major adverse effects.[7] Common side effects include dizziness, feeling tired, vomiting, and hallucinations.[7] Long-term effects of cannabis are not clear.[7] Concerns include memory and cognition problems, risk of addiction, schizophrenia in young people, and the risk of children taking it by accident.[6]

Many cultures have used cannabis for therapeutic purposes for thousands of years.[9] Some American medical organizations have requested removal of cannabis from the list of Schedule I controlled substances, emphasizing that rescheduling would enable more extensive research and regulatory oversight to ensure safe access.[10][11] Others oppose its legalization, such as the American Academy of Pediatrics.[12]

Medical cannabis can be administered through various methods, including capsules, lozenges, tinctures, dermal patches, oral or dermal sprays, cannabis edibles, and vaporizing or smoking dried buds. Synthetic cannabinoids are available for prescription use in some countries, such as synthetic delta-9-THC and nabilone.

Countries that allow the medical use of whole-plant cannabis include Argentina, Australia, Canada, Chile, Colombia, Germany, Greece, Israel, Italy, the Netherlands, Peru, Poland, Portugal, Spain, and Uruguay. In the United States, 38 states and the District of Columbia have legalized cannabis for medical purposes, beginning with the passage of California's Proposition 215 in 1996.[13] Although cannabis remains prohibited for any use at the federal level, the Rohrabacher–Farr amendment was enacted in December 2014, limiting the ability of federal law to be enforced in states where medical cannabis has been legalized. This amendment reflects an increasing bipartisan acknowledgment of the potential therapeutic uses of cannabis and the significance of state-level policymaking in this area.

Classification[edit | edit source]

In the U.S., the National Institute on Drug Abuse defines medical cannabis as "using the whole, unprocessed marijuana plant or its basic extracts to treat symptoms of illness and other conditions".[14]

A cannabis plant includes more than 400 different chemicals, of which about 70 are cannabinoids.[15] In comparison, typical government-approved medications contain only one or two chemicals.[15] The number of active chemicals in cannabis is one reason why treatment with cannabis is difficult to classify and study.[15]

A 2014 review stated that the variations in ratio of CBD-to-THC in botanical and pharmaceutical preparations determines the therapeutic vs psychoactive effects (CBD attenuates THC's psychoactive effects[16]) of cannabis products.[17]

Medical uses[edit | edit source]

Cannabis as illustrated in Köhler's Book of Medicinal Plants, 1897

Overall, research into the health effects of medical cannabis has been of low quality and it is not clear whether it is a useful treatment for any condition, or whether harms outweigh any benefit.[18] There is no consistent evidence that it helps with chronic pain and muscle spasms.[18]

Low quality evidence suggests its use for reducing nausea during chemotherapy, improving appetite in HIV/AIDS, improving sleep, and improving tics in Tourette syndrome.[7] When usual treatments are ineffective, cannabinoids have also been recommended for anorexia, arthritis, glaucoma,[19] and migraine.[20]

It is unclear whether American states might be able to mitigate the adverse effects of the opioid epidemic by prescribing medical cannabis as an alternative pain management drug.[21]

Cannabis should not be used in pregnancy.[22]

Insomnia[edit | edit source]

Research analyzing data from the National Health and Nutrition Examination Survey (NHANES) did not find significant differences in sleep duration between cannabis users and non-users. This suggests that while some individuals may perceive benefits from cannabis use in terms of sleep, it may not significantly change overall sleep patterns across the general population.[23]

A review of literature up to 2018 indicates that cannabidiol (CBD) may have therapeutic potential for the treatment of insomnia. CBD, a non-psychoactive component of cannabis, is of particular interest due to its potential to influence sleep without the psychoactive effects associated with tetrahydrocannabinol (THC).[24]

Nausea and vomiting[edit | edit source]

Medical cannabis is somewhat effective in chemotherapy-induced nausea and vomiting (CINV)[6][19] and may be a reasonable option in those who do not improve following preferential treatment.[25] Comparative studies have found cannabinoids to be more effective than some conventional antiemetics such as prochlorperazine, promethazine, and metoclopramide in controlling CINV,[26] but these are used less frequently because of side effects including dizziness, dysphoria, and hallucinations.[27][28] Long-term cannabis use may cause nausea and vomiting, a condition known as cannabinoid hyperemesis syndrome (CHS).[29]

A 2016 Cochrane review said that cannabinoids were "probably effective" in treating chemotherapy-induced nausea in children, but with a high side-effect profile (mainly drowsiness, dizziness, altered moods, and increased appetite). Less common side effects were "ocular problems, orthostatic hypotension, muscle twitching, pruritus, vagueness, hallucinations, lightheadedness and dry mouth".[30]

HIV/AIDS[edit | edit source]

Evidence is lacking for both efficacy and safety of cannabis and cannabinoids in treating patients with HIV/AIDS or for anorexia associated with AIDS. As of 2013, current studies suffer from the effects of bias, small sample size, and lack of long-term data.[31]

Pain[edit | edit source]

A 2021 review found little effect of using non-inhaled cannabis to relieve chronic pain.[8] According to a 2019 systematic review, there have been inconsistent results of using cannabis for neuropathic pain, spasms associated with multiple sclerosis and pain from rheumatic disorders, but was not effective treating chronic cancer pain. The authors state that additional randomized controlled trials of different cannabis products are necessary to make conclusive recommendations.[18]

When cannabis is inhaled to relieve pain, blood levels of cannabinoids rise faster than when oral products are used, peaking within three minutes and attaining an analgesic effect in seven minutes.[32]

A 2011 review considered cannabis to be generally safe,[33] and it appears safer than opioids in palliative care.[34]

A 2022 review concluded the pain relief experienced after using medical cannabis is due to the placebo effect, especially given widespread media attention that sets the expectation for pain relief.[35]

Neurological conditions[edit | edit source]

Cannabis' efficacy is not clear in treating neurological problems, including multiple sclerosis (MS) and movement problems.[17] Evidence also suggests that oral cannabis extract is effective for reducing patient-centered measures of spasticity.[17] A trial of cannabis is deemed to be a reasonable option if other treatments have not been effective.[6] [by whom?] 

Its use for MS is approved in ten countries.[6][36]Template:COI source A 2012 review found no problems with tolerance, abuse, or addiction.[37]  In the United States, cannabidiol, one of the cannabinoids found in the marijuana plant, has been approved for treating two severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome.[38]

Mental health[edit | edit source]

Further information: Cannabis use and trauma and Posttraumatic stress disorder § Cannabinoids


A 2019 systematic review found that there is a lack of evidence that cannabinoids are effective in treating depressive or anxiety disorders, attention-deficit hyperactivity disorder (ADHD), Tourette syndrome, post-traumatic stress disorder, or psychosis.[39]

Research indicates that cannabis, particularly CBD, may have anxiolytic (anxiety-reducing) effects. A study found that CBD significantly reduced anxiety during a simulated public speaking test for individuals with social anxiety disorder. However, the relationship between cannabis use and anxiety symptoms is complex, and while some users report relief, the overall evidence from observational studies and clinical trials remains inconclusive. Cannabis is often used by people to cope with anxiety, yet the efficacy and safety of cannabis for treating anxiety disorders is yet to be researched.[40][41]

Cannabis use, especially at high doses, is associated with a higher risk of psychosis, particularly in individuals with a genetic predisposition to psychotic disorders like schizophrenia. Some studies have shown that cannabis can trigger a temporary psychotic episode, which may increase the risk of developing a psychotic disorder later.[42]

The impact of cannabis on depression is less clear. Some studies suggest a potential increase in depression risk among adolescents who use cannabis, though findings are inconsistent across studies.[42]

Adverse effects[edit | edit source]

American medical hashish

Medical use[edit | edit source]

There is insufficient data to draw strong conclusions about the safety of medical cannabis.[43] Typically, adverse effects of medical cannabis use are not serious;[6] they include tiredness, dizziness, increased appetite, and cardiovascular and psychoactive effects. Other effects can include impaired short-term memory; impaired motor coordination; altered judgment; and paranoia or psychosis at high doses.[44] Tolerance to these effects develops over a period of days or weeks. The amount of cannabis normally used for medicinal purposes is not believed to cause any permanent cognitive impairment in adults, though long-term treatment in adolescents should be weighed carefully as they are more susceptible to these impairments. Withdrawal symptoms are rarely a problem with controlled medical administration of cannabinoids. The ability to drive vehicles or to operate machinery may be impaired until a tolerance is developed.[25] Although supporters of medical cannabis say that it is safe,[43] further research is required to assess the long-term safety of its use.[27][45]

Cognitive effects[edit | edit source]

Further information: long-term effects of cannabis

Recreational use of cannabis is associated with cognitive deficits, especially for those who begin to use cannabis in adolescence. As of 2021 

there is a lack of research into long-term cognitive effects of medical use of cannabis, but one 12-month observational study reported that "MC patients demonstrated significant improvements on measures of executive function and clinical state over the course of 12 months".[46]

Impact on psychosis[edit | edit source]

Exposure to THC can cause acute transient psychotic symptoms in healthy individuals and people with schizophrenia.[16]

A 2007 meta analysis concluded that cannabis use reduced the average age of onset of psychosis by 2.7 years relative to non-cannabis use.[47] A 2005 meta analysis concluded that adolescent use of cannabis increases the risk of psychosis, and that the risk is dose-related.[48] A 2004 literature review on the subject concluded that cannabis use is associated with a two-fold increase in the risk of psychosis, but that cannabis use is "neither necessary nor sufficient" to cause psychosis.[49] A French review from 2009 came to a conclusion that cannabis use, particularly that before age 15, was a factor in the development of schizophrenic disorders.[50]

Pharmacology[edit | edit source]

The genus Cannabis contains two species which produce useful amounts of psychoactive cannabinoids: Cannabis indica and Cannabis sativa, which are listed as Schedule I medicinal plants in the US;[6] a third species, Cannabis ruderalis, has few psychogenic properties.[6] Cannabis contains more than 460 compounds;[9] at least 80 of these are cannabinoids[51][52] – chemical compounds that interact with cannabinoid receptors in the brain.[6] As of 2012, more than 20 cannabinoids were being studied by the U.S. FDA.[53]

The most psychoactive cannabinoid found in the cannabis plant is tetrahydrocannabinol (or delta-9-tetrahydrocannabinol, commonly known as THC).[9] Other cannabinoids include delta-8-tetrahydrocannabinol, cannabidiol (CBD), cannabinol (CBN), cannabicyclol (CBL), cannabichromene (CBC) and cannabigerol (CBG); they have less psychotropic effects than THC, but may play a role in the overall effect of cannabis.[9] The most studied are THC, CBD and CBN.[54]

CB1 and CB2 are the primary cannabinoid receptors responsible for several of the effects of cannabinoids, although other receptors may play a role as well. Both belong to a group of receptors called G protein-coupled receptors (GPCRs). CB1 receptors are found in very high levels in the brain and are thought to be responsible for psychoactive effects.[55] CB2 receptors are found peripherally throughout the body and are thought to modulate pain and inflammation.[56]

Absorption[edit | edit source]

Cannabinoid absorption is dependent on its route of administration.

Inhaled and vaporized THC have similar absorption profiles to smoked THC, with a bioavailability ranging from 10 to 35%. Oral administration has the lowest bioavailability of approximately 6%, variable absorption depending on the vehicle used, and the longest time to peak plasma levels (2 to 6 hours) compared to smoked or vaporized THC.[57]

Similar to THC, CBD has poor oral bioavailability, approximately 6%. The low bioavailability is largely attributed to significant first-pass metabolism in the liver and erratic absorption from the gastrointestinal tract. However, oral administration of CBD has a faster time to peak concentrations (2 hours) than THC.[57]

Due to the poor bioavailability of oral preparations, alternative routes of administration have been studied, including sublingual and rectal. These alternative formulations maximize bioavailability and reduce first-pass metabolism. Sublingual administration in rabbits yielded bioavailability of 16% and time to peak concentration of 4 hours.[58] Rectal administration in monkeys doubled bioavailability to 13.5% and achieved peak blood concentrations within 1 to 8 hours after administration.[59]

Distribution[edit | edit source]

Like cannabinoid absorption, distribution is also dependent on route of administration. Smoking and inhalation of vaporized cannabis have better absorption than do other routes of administration, and therefore also have more predictable distribution.[59][60] THC is highly protein bound once absorbed, with only 3% found unbound in the plasma. It distributes rapidly to highly vascularized organs such as the heart, lungs, liver, spleen, and kidneys, as well as to various glands. Low levels can be detected in the brain, testes, and unborn fetuses, all of which are protected from systemic circulation via barriers.[61] THC further distributes into fatty tissues a few days after administration due to its high lipophilicity, and is found deposited in the spleen and fat after redistribution.[60][62][63]

Metabolism[edit | edit source]

Delta-9-THC is the primary molecule responsible for the effects of cannabis. Delta-9-THC is metabolized in the liver and turns into 11-OH-THC.[64] 11-OH-THC is the first metabolic product in this pathway. Both Delta-9-THC and 11-OH-THC are psychoactive. The metabolism of THC into 11-OH-THC plays a part in the heightened psychoactive effects of edible cannabis.[65]

Next, 11-OH-THC is metabolized in the liver into 11-COOH-THC, which is the second metabolic product of THC.[66] 11-COOH-THC is not psychoactive.[64]

Ingestion of edible cannabis products lead to a slower onset of effect than the inhalation of it because the THC travels to the liver first through the blood before it travels to the rest of the body. Inhaled cannabis can result in THC going directly to the brain, where it then travels from the brain back to the liver in recirculation for metabolism.[64] Eventually, both routes of metabolism result in the metabolism of psychoactive THC to inactive 11-COOH-THC.

Excretion[edit | edit source]

Due to substantial metabolism of THC and CBD, their metabolites are excreted mostly via feces, rather than by urine.[57][67] After delta-9-THC is hydroxylated into 11-OH-THC via CYP2C9, CYP2C19, and CYP3A4, it undergoes phase II metabolism into more than 30 metabolites, a majority of which are products of glucuronidation. Approximately 65% of THC is excreted in feces and 25% in the urine, while the remaining 10% is excreted by other means.[57] The terminal half-life of THC is 25 to 36 hours,[68] whereas for CBD it is 18 to 32 hours.[67]

CBD is hydroxylated by P450 liver enzymes into 7-OH-CBD. Its metabolites are products of primarily CYP2C19 and CYP3A4 activity, with potential activity of CYP1A1, CYP1A2, CYP2C9, and CYP2D6.[69] Similar to delta-9-THC, a majority of CBD is excreted in feces and some in the urine.[57] The terminal half-life is approximately 18–32 hours.[70]

Administration[edit | edit source]

Illustrating various forms of medicinal cannabis

Smoking has been the means of administration of cannabis for many users, but it is not suitable for the use of cannabis as a medicine.[71] It was the most common method of medical cannabis consumption in the US as of 2013

.[6] It is difficult to predict the pharmacological response to cannabis because concentration of cannabinoids varies widely, as there are different ways of preparing it for consumption (smoked, applied as oils, eaten, infused into other foods, or drunk) and a lack of production controls.[6] The potential for adverse effects from smoke inhalation makes smoking a less viable option than oral preparations.[71] Cannabis vaporizers have gained popularity because of a perception among users that fewer harmful chemicals are ingested when components are inhaled via aerosol rather than smoke.[6] Cannabinoid medicines are available in pill form (dronabinol and nabilone) and liquid extracts formulated into an oromucosal spray (nabiximols).[6] Oral preparations are "problematic due to the uptake of cannabinoids into fatty tissue, from which they are released slowly, and the significant first-pass liver metabolism, which breaks down Δ9THC and contributes further to the variability of plasma concentrations".[71]

The US Food and Drug Administration (FDA) has not approved smoked cannabis for any condition or disease, as it deems that evidence is lacking concerning safety and efficacy.[72] The FDA issued a 2006 advisory against smoked medical cannabis stating: "marijuana has a high potential for abuse, has no currently accepted medical use in treatment in the United States, and has a lack of accepted safety for use under medical supervision."[72]

History[edit | edit source]

Main article: History of medical cannabis


Ancient[edit | edit source]

Cannabis, called má 麻 (meaning "hemp; cannabis; numbness") or dàmá 大麻 (with "big; great") in Chinese, was used in Taiwan for fiber starting about 10,000 years ago.[73] The botanist Hui-lin Li wrote that in China, "The use of Cannabis in medicine was probably a very early development. Since ancient humans used hemp seed as food, it was quite natural for them to also discover the medicinal properties of the plant."[74] Emperor Shen-Nung, who was also a pharmacologist, wrote a book on treatment methods in 2737 BCE that included the medical benefits of cannabis. He recommended the substance for many ailments, including constipation, gout, rheumatism, and absent-mindedness.[75] Cannabis is one of the 50 "fundamental" herbs in traditional Chinese medicine.[76]

The Ebers Papyrus (c. 1550 BCE ) from Ancient Egypt describes medical cannabis.[77] The ancient Egyptians used hemp (cannabis) in suppositories for relieving the pain of hemorrhoids.[78]

Surviving texts from ancient India confirm that cannabis' psychoactive properties were recognized, and doctors used it for treating a variety of illnesses and ailments, including insomnia, headaches, gastrointestinal disorders, and pain, including during childbirth.[79]

The Ancient Greeks used cannabis to dress wounds and sores on their horses,[80] and in humans, dried leaves of cannabis were used to treat nose bleeds, and cannabis seeds were used to expel tapeworms.[80]

In the medieval Islamic world, Arabic physicians made use of the diuretic, antiemetic, antiepileptic, anti-inflammatory, analgesic and antipyretic properties of Cannabis sativa, and used it extensively as medication from the 8th to 18th centuries.[81]

Landrace strains[edit | edit source]

Evolution of cultivated cannabis strains. The cultivar, Cannabis ruderalis, still grows wild today.

Cannabis seeds may have been used for food, rituals or religious practices in ancient Europe and China.[82]: 19–22  Harvesting the plant led to the spread of cannabis throughout Eurasia about 10,000 to 5,000 years ago, with further distribution to the Middle East and Africa about 2,000 to 500 years ago.[82]: 18–19  A landrace strain of cannabis developed over centuries.[83] They are cultivars of the plant that originated in one specific region.

Widely cultivated strains of cannabis, such as "Afghani" or "Hindu Kush", are indigenous to the Pakistan and Afghanistan regions, while "Durban Poison" is native to Africa.[82]: 45–48  There are approximately 16 landrace strains of cannabis identified from Pakistan, Jamaica, Africa, Mexico, Central America and Asia.[84]

Modern[edit | edit source]

An Irish physician, William Brooke O'Shaughnessy, is credited with introducing cannabis to Western medicine.[85] O'Shaughnessy discovered cannabis in the 1830s while living abroad in India, where he conducted numerous experiments investigating the drug's medical utility (noting in particular its analgesic and anticonvulsant effects).[86] He returned to England with a supply of cannabis in 1842, after which its use spread through Europe and the United States.[87] In 1845 French physician Jacques-Joseph Moreau published a book about the use of cannabis in psychiatry.[88] In 1850 cannabis was entered into the United States Pharmacopeia.[86] An anecdotal report of Cannabis indica as a treatment for tetanus appeared in Scientific American in 1880.[89]

The use of cannabis in medicine began to decline by the end of the 19th century, due to difficulty in controlling dosages and the rise in popularity of synthetic and opium-derived drugs.[87] Also, the advent of the hypodermic syringe allowed these drugs to be injected for immediate effect, in contrast to cannabis which is not water-soluble and therefore cannot be injected.[87]

In the United States, the medical use of cannabis further declined with the passage of the Marihuana Tax Act of 1937, which imposed new regulations and fees on physicians prescribing cannabis.[90] Cannabis was removed from the U.S. Pharmacopeia in 1941, and officially banned for any use with the passage of the Controlled Substances Act of 1970.[87]

Cannabis began to attract renewed interest as medicine in the 1970s and 1980s, in particular due to its use by cancer and AIDS patients who reported relief from the effects of chemotherapy and wasting syndrome.[91] In 1996, California became the first U.S. state to legalize medical cannabis in defiance of federal law.[92] In 2001, Canada became the first country to adopt a system regulating the medical use of cannabis.[93]

  • The use of cannabis, at least as fiber, has been shown to go back at least 10,000 years in Taiwan. "Dà má" (Pinyin pronunciation) is the Chinese expression for cannabis, the first character meaning "big" and the second character meaning "hemp".

  • Cannabis indica fluid extract, American Druggists Syndicate, pre-1937

  • An advertisement for cannabis americana distributed by a pharmacist in New York in 1917

  • The Ebers Papyrus (c. 1550 BCE ) from Ancient Egypt has a prescription for medical marijuana applied directly for inflammation.

Society and culture[edit | edit source]

Legal status[edit | edit source]

Map of world medical cannabis laws
Legal status of (whole-plant) medical cannabis worldwide (only de jure; may not reflect actual access in these countries)
  Legal as authorized by a physician
  Legal for any use (no prescription required)
See also countries that have decriminalized or where enforcement is limited.

Countries that have legalized the medical use of cannabis include Argentina,[94] Australia,[95] Brazil,[96] Canada,[97] Chile,[97] Colombia,[97] Costa Rica,[98] Croatia,[99] Cyprus,[100] Czech Republic,[97] Finland,[101] Germany,[102] Greece,[103] Israel,[104] Italy,[105] Jamaica,[106] Lebanon,[107] Luxembourg,[108] Malta,[109] Morocco,[110] the Netherlands,[97] New Zealand,[111] North Macedonia,[112] Panama,[113] Peru,[114] Poland,[115] Portugal,[116] Rwanda,[117] Sri Lanka,[118] Switzerland,[119] Thailand,[120] the United Kingdom,[121] and Uruguay.[97] Other countries have more restrictive laws that allow only the use of isolated cannabinoid drugs such as Sativex or Epidiolex.[122][123] Countries with the most relaxed policies include Canada,[124] the Netherlands,[97] Thailand,[125] and Uruguay,[97] where cannabis can be purchased without need for a prescription. In Mexico, THC content of medical cannabis is limited to one percent.[126] In the United States, the legality of medical cannabis varies by state.[13]

However, in many of these countries, access may not always be possible under the same conditions.

International law[edit | edit source]

Cannabis and its derivatives are subject to regulation under three United Nations drug control treaties: the 1961 Single Convention on Narcotic Drugs, the 1971 Convention on Psychotropic Substances, and the 1988 Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances.[127]

Cannabis and cannabis resin are classified as a Schedule I drug under the Single Convention treaty, meaning that medical use is considered "indispensible for the relief of pain and suffering" but that it is considered to be an addictive medication with risks of abuse.[128] Countries have an obligation to provide access and sufficient availability of drugs listed in Schedule I for the purposes of medical uses.[129][130]

Prior to December 2020 cannabis and cannabis resin were also included in Schedule IV, a more restrictive level of control, which is for only the most dangerous drugs such as heroin and fentanyl.[131] They were removed after an independent scientific assessment by the World Health Organization in 2018-1029.

Member nations of the UN Commission on Narcotic Drugs voted 27–25 to remove it from Schedule IV on 2 December 2020,[132] following a World Health Organization recommendation for removal in January 2019.[133][134]

United States[edit | edit source]

In the United States, the use of cannabis for medical purposes is legal in 38 states, four out of five permanently inhabited U.S. territories, and the District of Columbia.[13] An additional 10 states have more restrictive laws allowing the use of low-THC products.[13] Cannabis remains illegal at the federal level under the Controlled Substances Act, which classifies it as a Schedule I drug with a high potential for abuse and no accepted medical use. In December 2014, however, the Rohrabacher–Farr amendment was signed into law, prohibiting the Justice Department from prosecuting individuals acting in accordance with state medical cannabis laws.[135]

In the US, the FDA has approved two oral cannabinoids for use as medicine in 1985:[136] dronabinol (pure delta-9-THC; brand name Marinol) and nabilone (a synthetic neocannabinoid; brand name Cesamet).[6] In the US, they are both listed as Schedule II, indicating high potential for side effects and addiction.[53][137]

Economics[edit | edit source]

Distribution[edit | edit source]

Medical marijuana dispensary in Denver, Colorado

The method of obtaining medical cannabis varies by region and by legislation. In the US, most consumers grow their own or buy it from cannabis dispensaries in states where it is legal.[6][138] Marijuana vending machines for selling or dispensing cannabis are in use in the United States and are planned to be used in Canada.[139] In 2014, the startup Meadow began offering on-demand delivery of medical marijuana in the San Francisco Bay Area, through their mobile app.[140]

Almost 70% of medical cannabis is exported from the United Kingdom, according to a 2017 United Nations report, with much of the remaining amount coming from Canada and the Netherlands.[141]

Insurance[edit | edit source]

In the United States, health insurance companies may not pay for a medical marijuana prescription as the Food and Drug Administration must approve any substance for medicinal purposes. Before this can happen, the FDA must first permit the study of the medical benefits and drawbacks of the substance, which it has not done since it was placed on Schedule I of the Controlled Substances Act in 1970. Therefore, all expenses incurred fulfilling a medical marijuana prescription will possibly be incurred as out-of-pocket.[142] However, the New Mexico Court of Appeals has ruled that workers' compensation insurance must pay for prescribed marijuana as part of the state's Medical Cannabis Program.[143]

Positions of medical organizations[edit | edit source]

Medical organizations that have issued statements in support of allowing access to medical cannabis include the American Nurses Association,[10] American Public Health Association,[144] American Medical Student Association,[145] National Multiple Sclerosis Society,[146] Epilepsy Foundation,[147] and Leukemia & Lymphoma Society.[148]

Organizations that oppose the legalization of medical cannabis include the American Academy of Pediatrics (AAP)[12] and American Psychiatric Association.[149] However, the AAP also supports rescheduling for the purpose of facilitating research.[12]

The American Medical Association[150] and American College of Physicians[151] do not take a position on the legalization of medical cannabis, but have called for the Schedule I classification to be reviewed. The American Academy of Family Physicians[11] and American Society of Addiction Medicine[152] also do not take a position, but do support rescheduling to better facilitate research. The American Heart Association says that "many of the concerning health implications of cannabis include cardiovascular diseases" but that it supports rescheduling to allow "more nuanced ... marijuana legislation and regulation" and to "reflect the existing science behind cannabis".[153] The American Cancer Society[154] and American Psychological Association[155] have noted the obstacles that exist for conducting research on cannabis, and have called on the federal government to better enable scientific study of the drug.

Cancer Research UK say that while cannabis is being studied for therapeutic potential, "claims that there is solid "proof" that cannabis or cannabinoids can cure cancer is highly misleading to patients and their families, and builds a false picture of the state of progress in this area".[156]

Nonproprietary names[edit | edit source]

There are three International Nonproprietary Name (INN) granted for cannabinoids: two plant-derived phytocannabinoids and one neocannabinoid:

  • Dronabinol is the INN for delta-9-THC[157][158] (there is a common confusion according to which the word "dronabinol" would only refer to synthetic delta-9-THC, which is incorrect[159]).
  • Cannabidiol is also the official INN for the molecule, granted in 2017.[160]
  • Nabilone is the INN for a synthetic cannabinoid analog (not present in Cannabis plants).

Nabiximols is the generic name (but not recognized as an INN) of a mixture of Cannabidiol and Dronabinol. Its most common form is the oromucosal spray derived from two strains of Cannabis sativa and containing THC and CBD traded under the brand name Sativex®.[53] It is not approved in the United States, but is approved in several European countries, Canada, and New Zealand as of 2013.[6]

Generic
name 		Brand
name(s) 		Country (non-exhaustive) Licensed indications
Nabilone Cesamet U.S., Canada Antiemetic (treatment of nausea or vomiting) associated with chemotherapy that has failed to respond adequately to conventional therapy[6]
Dronabinol Marinol
Syndros U.S. Anorexia associated with AIDS–related weight loss[6]
Nabiximols Sativex Canada, New Zealand,
majority of the EU[161] 		Limited treatment for spasticity and neuropathic pain associated with multiple sclerosis and intractable cancer pain.[6]

As an antiemetic, these medications are usually used when conventional treatment for nausea and vomiting associated with cancer chemotherapy fail to work.[6]

Nabiximols is used for treatment of spasticity associated with MS when other therapies have not worked, and when an initial trial demonstrates "meaningful improvement".[6] Trials for FDA approval in the US are underway.[6] It is also approved in several European countries for overactive bladder and vomiting.[53] When sold under the trade name Sativex as a mouth spray, the prescribed daily dose in Sweden delivers a maximum of 32.4 mg of THC and 30 mg of CBD; mild to moderate dizziness is common during the first few weeks.[162]

Relative to inhaled consumption, peak concentration of oral THC is delayed, and it may be difficult to determine optimal dosage because of variability in patient absorption.[6]

In 1964, Albert Lockhart and Manley West began studying the health effects of traditional cannabis use in Jamaican communities. They developed, and in 1987 gained permission to market, the pharmaceutical "Canasol", one of the first cannabis extracts.[163]

Research[edit | edit source]

Main article: Medical cannabis research


A 2022 review concluded that "oral, synthetic cannabis products with high THC-to-CBD ratios and sublingual, extracted cannabis products with comparable THC-to-CBD ratios may be associated with short-term improvements in chronic pain and increased risk for dizziness and sedation."[164]

See also[edit | edit source]

References[edit | edit source]

  1. ↑ , Medicinal cannabis, Australian Prescriber, Vol. 38(Issue: 6), pp. 212–15, DOI: 10.18773/austprescr.2015.072, PMID: 26843715, PMC: 4674028,
  2. ↑ What is medical marijuana? Full text, National Institute of Drug Abuse, July 2015, Accessed on: 19 April 2016.
  3. ↑ , Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review, BMC Psychiatry, Vol. 20(Issue: 1), DOI: 10.1186/s12888-019-2409-8, PMID: 31948424, PMC: 6966847,
  4. ↑ O'Brien, Kylie, Medicinal Cannabis: Issues of evidence, European Journal of Integrative Medicine, Vol. 28 pp. 114–120, DOI: 10.1016/j.eujim.2019.05.009, Full text,
  5. ↑ , Release the strains, Nature Medicine, Vol. 21(Issue: 9), DOI: 10.1038/nm.3946, PMID: 26340110,
  6. ↑ 6.00 6.01 6.02 6.03 6.04 6.05 6.06 6.07 6.08 6.09 6.10 6.11 6.12 6.13 6.14 6.15 6.16 6.17 6.18 6.19 6.20 6.21 6.22 , The pharmacologic and clinical effects of medical cannabis, Pharmacotherapy, Vol. 33(Issue: 2), pp. 195–209, DOI: 10.1002/phar.1187, PMID: 23386598, Full text, Accessed on: 11 November 2017.
  7. ↑ 7.0 7.1 7.2 7.3 7.4 , Cannabinoids for Medical Use: A Systematic Review and Meta-analysis, JAMA, Vol. 313(Issue: 24), pp. 2456–73, DOI: 10.1001/jama.2015.6358, PMID: 26103030,
  8. ↑ 8.0 8.1 , Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials, BMJ, Vol. 374 pp. n1034, DOI: 10.1136/bmj.n1034, PMID: 34497047, Full text, Accessed on: 9 September 2021.
  9. ↑ 9.0 9.1 9.2 9.3 , Cannabinoids in medicine: A review of their therapeutic potential, Journal of Ethnopharmacology, Vol. 105(Issue: 1–2), pp. 1–25, DOI: 10.1016/j.jep.2006.02.001, PMID: 16540272,
  10. ↑ 10.0 10.1
  11. ↑ 11.0 11.1 , AAFP Releases Marijuana, Cannabinoids Position Paper Full text, American Academy of Family Physicians, 20 September 2019, Accessed on: 6 October 2019.
  12. ↑ 12.0 12.1 12.2
  13. ↑ 13.0 13.1 13.2 13.3 State Medical Marijuana Laws Full text, National Conference of State Legislatures, 12 September 2022, Accessed on: 6 October 2022.
  14. ↑ Marijuana as Medicine Full text, , National Institute on Drug Abuse, July 2019, Accessed on: 19 April 2016.
  15. ↑ 15.0 15.1 15.2 Up in Smoke: Does Medical Marijuana Work? Full text, Consumer Reports, 28 April 2016, Accessed on: 24 May 2016.
  16. ↑ 16.0 16.1 , Cannabidiol as a potential treatment for psychosis, European Neuropsychopharmacology, Vol. 24(Issue: 1), pp. 51–64, DOI: 10.1016/j.euroneuro.2013.11.002, PMID: 24309088, Full text, Accessed on: 9 July 2016.
  17. ↑ 17.0 17.1 17.2 , Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology, Neurology, Vol. 82(Issue: 17), pp. 1556–1563, DOI: 10.1212/WNL.0000000000000363, PMID: 24778283, PMC: 4011465,
  18. ↑ 18.0 18.1 18.2 , Benefits and harms of medical cannabis: a scoping review of systematic reviews, Syst Rev, Vol. 8(Issue: 1), DOI: 10.1186/s13643-019-1243-x, PMID: 31823819, PMC: 6905063,
  19. ↑ 19.0 19.1 , Safety and Toxicology of Cannabinoids, Neurotherapeutics, Vol. 12(Issue: 4), pp. 735–46, DOI: 10.1007/s13311-015-0380-8, PMID: 26269228, PMC: 4604177,
  20. ↑ Sex(ism), Drugs, and Migraines: Distillations Podcast and Transcript, Episode 237 Full text, Distillations, Science History Institute, 15 January 2019, Accessed on: 28 August 2019.
  21. ↑ , The use of cannabis in response to the opioid crisis: A review of the literature, Nursing Outlook, Vol. 66(Issue: 1), pp. 56–65, DOI: 10.1016/j.outlook.2017.08.012, PMID: 28993073,
  22. ↑ American College of Obstetricians Gynecologists Committee on Obstetric Practice, Committee Opinion No. 637: Marijuana Use During Pregnancy and Lactation, Obstetrics and Gynecology, Vol. 126(Issue: 1), pp. 234–38, DOI: 10.1097/01.AOG.0000467192.89321.a6, PMID: 26241291,
  23. ↑ , Recent cannabis use and nightly sleep duration in adults: a population analysis of the NHANES from 2005 to 2018, Regional Anesthesia & Pain Medicine, Vol. 47(Issue: 2), pp. 100–104, DOI: 10.1136/rapm-2021-103161, PMID: 34873024, Full text,
  24. ↑ , Treating insomnia symptoms with medicinal cannabis: a randomized, crossover trial of the efficacy of a cannabinoid medicine compared with placebo, SLEEP, Vol. 44(Issue: 11), DOI: 10.1093/sleep/zsab149, PMID: 34115851, PMC: 8598183,
  25. ↑ 25.0 25.1 , The therapeutic potential of cannabis and cannabinoids, Deutsches Ärzteblatt International, Vol. 109(Issue: 29–30), pp. 495–501, DOI: 10.3238/arztebl.2012.0495, PMID: 23008748, PMC: 3442177,
  26. ↑ , The intersection between cannabis and cancer in the United States, Critical Reviews in Oncology/Hematology, Vol. 83(Issue: 1), pp. 1–10, DOI: 10.1016/j.critrevonc.2011.09.008, PMID: 22019199,
  27. ↑ 27.0 27.1 , Adverse effects of medical cannabinoids: a systematic review, CMAJ, Vol. 178(Issue: 13), pp. 1669–78, DOI: 10.1503/cmaj.071178, PMID: 18559804, PMC: 2413308,
  28. ↑ , Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations, The Oncologist, Vol. 12(Issue: 9), pp. 1143–50, DOI: 10.1634/theoncologist.12-9-1143, PMID: 17914084, Full text,
  29. ↑ , Cannabinoid hyperemesis syndrome: a case series and review of previous reports, Psychosomatics, Vol. 53(Issue: 3), pp. 212–19, DOI: 10.1016/j.psym.2012.01.003, PMID: 22480624,
  30. ↑ , Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood, The Cochrane Database of Systematic Reviews, Vol. 2016(Issue: 2), pp. CD007786, DOI: 10.1002/14651858.CD007786.pub3, PMID: 26836199, PMC: 7073407, Full text, Accessed on: 23 September 2019.
  31. ↑ , The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS, The Cochrane Database of Systematic Reviews, Vol. 4(Issue: 4), pp. CD005175, DOI: 10.1002/14651858.CD005175.pub3, PMID: 23633327,
  32. ↑ , Efficacy of Cannabis-Based Medicines for Pain Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Pain Physician, Vol. 20(Issue: 6), pp. E755–96, DOI: 10.36076/ppj.20.5.E755, PMID: 28934780, Full text, Accessed on: 12 January 2018.
  33. ↑ , Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials, British Journal of Clinical Pharmacology, Vol. 72(Issue: 5), pp. 735–44, DOI: 10.1111/j.1365-2125.2011.03970.x, PMID: 21426373, PMC: 3243008,
  34. ↑ , Cannabis in palliative medicine: improving care and reducing opioid-related morbidity, The American Journal of Hospice & Palliative Care, Vol. 28(Issue: 5), pp. 297–303, DOI: 10.1177/1049909111402318, PMID: 21444324,
  35. ↑ , Placebo Response and Media Attention in Randomized Clinical Trials Assessing Cannabis-Based Therapies for PainA Systematic Review and Meta-analysis, JAMA Network Open, Vol. 5(Issue: 11), pp. e2243848, DOI: 10.1001/jamanetworkopen.2022.43848, PMID: 36441553, PMC: 9706362,
  36. ↑ , Medical marijuana: medical necessity versus political agenda, Medical Science Monitor, Vol. 17(Issue: 12), pp. RA249–61, DOI: 10.12659/MSM.882116, PMID: 22129912, PMC: 3628147,
  37. ↑ , [Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids], Revista de Neurología, Vol. 55(Issue: 7), pp. 421–30, PMID: 23011861,
  38. ↑ Commissioner, Office of the, FDA and Marijuana, FDA, Full text, Accessed on: 16 December 2019.
  39. ↑ , Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis, Lancet Psychiatry, Vol. 6(Issue: 12), pp. 995–1010, DOI: 10.1016/S2215-0366(19)30401-8, PMID: 31672337, PMC: 6949116,
  40. ↑ Anxiety and Cannabis: A Review of Recent Research Full text, Medical Cannabis Research Center, 2023-04-10, Accessed on: 2024-04-09.
  41. ↑ , Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review, BMC Psychiatry, Vol. 20(Issue: 1), DOI: 10.1186/s12888-019-2409-8, PMID: 31948424, PMC: 6966847,
  42. ↑ 42.0 42.1 Is there a link between marijuana use and psychiatric disorders? | National Institute on Drug Abuse (NIDA) Full text, Abuse, National Institute on Drug, nida.nih.gov, 2023-05-08, Accessed on: 2024-04-09.
  43. ↑ 43.0 43.1 , Pain, Oxford University Press, 2012, ISBN 978-0-19-994274-9,
  44. ↑ , Association Between Cannabis and Psychosis: Epidemiologic Evidence, Biological Psychiatry, Vol. 79(Issue: 7), pp. 549–56, DOI: 10.1016/j.biopsych.2015.08.001, PMID: 26386480, Full text, Accessed on: 11 March 2020.
  45. ↑ Donald G, Medical Toxicology of Drug Abuse: Synthesized Chemicals and Psychoactive Plants, John Wiley & Sons, 2012, ISBN 978-0-471-72760-6, Accessed: 20 December 2015. Pages: 886–931,
  46. ↑ , An Observational, Longitudinal Study of Cognition in Medical Cannabis Patients over the Course of 12 Months of Treatment: Preliminary Results, Journal of the International Neuropsychological Society, Vol. 27(Issue: 6), pp. 648–60, DOI: 10.1017/S1355617721000114, PMID: 34261553,
  47. ↑ , Cannabis use and earlier onset of psychosis: a systematic meta-analysis, Archives of General Psychiatry, Vol. 68(Issue: 6), pp. 555–61, DOI: 10.1001/archgenpsychiatry.2011.5, PMID: 21300939,
  48. ↑ , Cannabis as a risk factor for psychosis: systematic review, Journal of Psychopharmacology, Vol. 19(Issue: 2), pp. 187–94, DOI: 10.1177/0269881105049040, PMID: 15871146,
  49. ↑ , Causal association between cannabis and psychosis: examination of the evidence, The British Journal of Psychiatry, Vol. 184(Issue: 2), pp. 110–17, DOI: 10.1192/bjp.184.2.110, PMID: 14754822,
  50. ↑ , [Is cannabis a vulnerability factor in schizophrenic disorders], Archives de Pédiatrie, Vol. 16(Issue: 9), pp. 1302–05, DOI: 10.1016/j.arcped.2009.03.016, PMID: 19640690,
  51. ↑ , Phytocannabinoids, CNS cells and development: a dead issue?, Drug and Alcohol Review, Vol. 29(Issue: 1), pp. 91–98, DOI: 10.1111/j.1465-3362.2009.00102.x, PMID: 20078688,
  52. ↑ , Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain, The Annals of Pharmacotherapy, Vol. 40(Issue: 2), pp. 251–60, DOI: 10.1345/aph.1G217, PMID: 16449552,
  53. ↑ 53.0 53.1 53.2 53.3 , Legalization, decriminalization & medicinal use of cannabis: a scientific and public health perspective, Missouri Medicine, 2012, Vol. 109(Issue: 2), pp. 90–98, PMID: 22675784, PMC: 6181739,
  54. ↑ , Medical consequences of marijuana use: a review of current literature, Current Psychiatry Reports, Vol. 15(Issue: 12), DOI: 10.1007/s11920-013-0419-7, PMID: 24234874, Full text, Accessed on: 12 July 2019.
  55. ↑ , Cannabinoid receptors: where they are and what they do, Journal of Neuroendocrinology, Vol. 20(Issue: Suppl 1), pp. 10–14, DOI: 10.1111/j.1365-2826.2008.01671.x, PMID: 18426493,
  56. ↑ , The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists, Current Medicinal Chemistry, Vol. 14(Issue: 8), pp. 917–36, DOI: 10.2174/092986707780363023, PMID: 17430144,
  57. ↑ 57.0 57.1 57.2 57.3 57.4 , Pharmacology of cannabinoids in the treatment of epilepsy, Epilepsy & Behavior, Vol. 70(Issue: Pt B), pp. 313–18, DOI: 10.1016/j.yebeh.2016.11.016, PMID: 28087250,
  58. ↑ , Sublingual administration of Delta9-tetrahydrocannabinol/beta-cyclodextrin complex increases the bioavailability of Delta9-tetrahydrocannabinol in rabbits, Life Sciences, Vol. 78(Issue: 17), pp. 1911–14, DOI: 10.1016/j.lfs.2005.08.025, PMID: 16266727,
  59. ↑ 59.0 59.1 , Human cannabinoid pharmacokinetics, Chemistry & Biodiversity, Vol. 4(Issue: 8), pp. 1770–804, DOI: 10.1002/cbdv.200790152, PMID: 17712819, PMC: 2689518,
  60. ↑ 60.0 60.1 , A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics, Cancer Chemotherapy and Pharmacology, Vol. 80(Issue: 3), pp. 441–49, DOI: 10.1007/s00280-017-3387-5, PMID: 28780725, PMC: 5573753,
  61. ↑ , The pharmacokinetics of THC in fat and brain: resulting functional responses to marihuana smoking, Human Psychopharmacology, Vol. 16(Issue: 3), pp. 247–55, DOI: 10.1002/hup.258, PMID: 12404577,
  62. ↑ , Medicinal Cannabis: History, Pharmacology, And Implications for the Acute Care Setting, P & T, Vol. 42(Issue: 3), pp. 180–88, PMID: 28250701, PMC: 5312634,
  63. ↑ , Marihuana and Medicine. online version, Springer Science & Business Media, 1999, ISBN 978-1-59259-710-9, Accessed: 20 September 2020.
  64. ↑ 64.0 64.1 64.2 , Human Metabolism of THC Full text, Sapiensoup Blog, 2016-12-21, Accessed on: 2017-11-01.
  65. ↑ 11-Hydroxy-THC - Increased Potency That Explains the Effect of Edibles? – Prof of Pot Full text, profofpot.com, 2 July 2016, Accessed on: 2017-11-01.
  66. ↑ Toxicology Litigation Support: Marijuana Full text, consultox.com, Accessed on: 2017-11-01.
  67. ↑ 67.0 67.1 , Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders, Epilepsia, Vol. 55(Issue: 6), pp. 791–802, DOI: 10.1111/epi.12631, PMID: 24854329, PMC: 4707667,
  68. ↑ , Pharmacokinetics and pharmacodynamics of cannabinoids, Clinical Pharmacokinetics, Vol. 42(Issue: 4), pp. 327–60, DOI: 10.2165/00003088-200342040-00003, PMID: 12648025,
  69. ↑ , Cannabinoids and Cytochrome P450 Interactions, Current Drug Metabolism, Vol. 17(Issue: 3), pp. 206–226, DOI: 10.2174/1389200217666151210142051, PMID: 26651971, Full text, Accessed on: 1 November 2017.
  70. ↑ , Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration, Biomedical & Environmental Mass Spectrometry, Vol. 13(Issue: 2), pp. 77–83, DOI: 10.1002/bms.1200130206, PMID: 2937482,
  71. ↑ 71.0 71.1 71.2 , Cannabinoids for Tourette's Syndrome, The Cochrane Database of Systematic Reviews, Vol. 2009(Issue: 4), pp. CD006565, DOI: 10.1002/14651858.CD006565.pub2, PMID: 19821373, PMC: 7387115,
  72. ↑ 72.0 72.1
  73. ↑ Ernest L., Marihuana: the first twelve thousand years, New York City:Plenum Publishers, 1980, ISBN 978-0-306-40496-2, Accessed: 29 October 2008. [page needed]
  74. ↑ Li, Hui-Lin (1974). "An Archaeological and Historical Account of Cannabis in China", Economic Botany 28.4:437–48, p. 444.
  75. ↑ Edward, Marijuana: The Second Trip, California:Glencoe Press, 1971,
  76. ↑ Ming, La Médecine chinoise par les plantes, Paris:Tchou, 1976, [page needed]
  77. ↑ Template:Unreliable source? The Ebers Papyrus The Oldest (confirmed) Written Prescriptions For Medical Marihuana era 1,550 BC Full text, , onlinepot.org, Accessed on: 10 June 2008.
  78. ↑ Pain, Stephanie, The Pharaoh's pharmacists Full text, New Scientist, Reed Business Information Ltd., 15 December 2007, Accessed on: 4 September 2017.
  79. ↑ , The religious and medicinal uses of Cannabis in China, India and Tibet, Journal of Psychoactive Drugs, 1981, Vol. 13(Issue: 1), pp. 23–34, DOI: 10.1080/02791072.1981.10471447, PMID: 7024492,
  80. ↑ 80.0 80.1 , The Medical Use of Cannabis Among the Greeks and Romans, Journal of Cannabis Therapeutics, 2002, Vol. 2(Issue: 2), pp. 51–70, DOI: 10.1300/J175v02n02_04, Full text, Accessed on: 8 November 2014.
  81. ↑ , The Therapeutic Use of Cannabis sativa (L.) in Arabic Medicine, Journal of Cannabis Therapeutics, 2001, Vol. 1 pp. 63–70, DOI: 10.1300/J175v01n01_05,
  82. ↑ 82.0 82.1 82.2 , The Pot Book: A Complete Guide to Cannabis. online version, New York:Simon and Schuster, ISBN 978-1-59477-898-8, Accessed: 22 April 2018.
  83. ↑ , Raven Biology of Plants, 8th edition, New York:W. H. Freeman and Company, ISBN 978-1-4292-1961-7, Pages: 213–17,
  84. ↑ , Raven Biology of Plants, 8th edition, New York:W.H. Freeman and Company, ISBN 978-1-4292-1961-7, Pages: 501–04,
  85. ↑ , Marijuana As Medicine?: The Science Beyond the Controversy. online version, National Academies Press, 2000, ISBN 978-0-309-06531-3, Accessed: 20 December 2015. Pages: 15–,
  86. ↑ 86.0 86.1 , Cannabis: A History, New York:St. Martin's Press, 2005, ISBN 978-0-312-42494-7,
  87. ↑ 87.0 87.1 87.2 87.3 , Marihuana, the Forbidden Medicine, Revised and expanded edition, Yale University Press, ISBN 978-0-300-07086-6,
  88. ↑ Hans Bangen:Geschichte der medikamentösen Therapie der Schizophrenie. Berlin 1992, p. 22.
  89. ↑ , Scientific American, "Successful Treatment of Tetanus". online version, Munn & Company, Accessed: 5 June 2021.
  90. ↑ , State Medical Marijuana Laws: Understanding the Laws and Their Limitations, Journal of Public Health Policy, Vol. 23(Issue: 4), pp. 413–39, DOI: 10.2307/3343240, PMID: 12532682, Full text, Accessed on: 20 March 2018.
  91. ↑ , Marijuana and Medicine – Assessing the Science Base Full text, , National Academy Press, 1999, Washington, D.C., Accessed on: 28 July 2017.
  92. ↑ History of Marijuana as Medicine – 2900 BC to Present Full text, ProCon.org, Accessed on: 27 July 2017.
  93. ↑ , Marijuana's journey to legal health treatment: the Canadian experience Full text, CBC News, 17 August 2009, Accessed on: 27 July 2017.
  94. ↑ , Argentina to Allow Medicinal Marijuana to Be Grown at Home Full text, The New York Times, 12 November 2020, Accessed on: 22 January 2023.
  95. ↑ , Medicinal Marijuana Legal In Australia Full text, Canstar, 28 February 2018, Accessed on: 16 July 2018.
  96. ↑ , Brazil Regulates Sale Of Medical Marijuana Products Full text, Benzinga, 3 December 2019, Accessed on: 10 December 2019.
  97. ↑ 97.0 97.1 97.2 97.3 97.4 97.5 97.6 97.7 , 10 Countries (Aside From the U.S.) Where Some Form of Medical Marijuana Is Legal Full text, The Motley Fool, 15 May 2016, Accessed on: 5 November 2017.
  98. ↑ , Costa Rica legalizes medicinal marijuana use, hemp growing Full text, Associated Press, 2 March 2022, Accessed on: 22 January 2023.
  99. ↑ , Croatia legalises marijuana for medical use Full text, Yahoo News, 15 October 2015, Accessed on: 4 November 2017.
  100. ↑ , Cyprus begins to distribute medical cannabis Full text, InCyprus, 22 May 2017, Accessed on: 11 November 2017.
  101. ↑ Legal status of cannabis in Finland – An overview Full text, Sensi Seeds, Accessed on: 4 November 2017.
  102. ↑ , Germany joins the global experiment on marijuana legalization Full text, CNN.com, 6 March 2017, Accessed on: 4 November 2017.
  103. ↑ , Greece legalises marijuana for medical purposes Full text, The Independent, 3 July 2017, Accessed on: 4 November 2017.
  104. ↑ , How the Booming Israeli Weed Industry Is Changing American Pot Full text, Rollingstone.com, 24 August 2017, Accessed on: 4 November 2017.
  105. ↑ Samuels, Gabriel, Italian army aims to produce "the best-quality" medical marijuana after finding current batches deficient Full text, The Independent, 26 July 2016, Accessed on: 4 November 2017.
  106. ↑ , Jamaica's Kaya Farms Becomes First Medical Marijuana Dispensary To Open Full text, marijuana.com, 19 March 2018, Accessed on: 16 July 2018.
  107. ↑ , Lebanon Legalizes Cannabis Farming for Medicinal Use Full text, The New York Times, 21 April 2020, Accessed on: 25 April 2020.
  108. ↑ , Cannabis for medical use legalised in Luxembourg Full text, Luxembourg Times, 29 June 2018, Accessed on: 8 July 2018.
  109. ↑ , Malta has officially legalised medical cannabis Full text, Malta Today, 27 March 2018, Accessed on: 24 August 2018.
  110. ↑ , Morocco: Bill to legalise cannabis enters into force Full text, Middle East Monitor, 31 July 2021, Accessed on: 22 January 2023.
  111. ↑ , New Zealand passes laws to make medical marijuana widely available Full text, The Guardian, 11 December 2018, Accessed on: 20 January 2019.
  112. ↑ , Macedonia Allows Medical Marijuana in Pharmacies Full text, Balkan Insight, 1 June 2016, Accessed on: 4 November 2017.
  113. ↑ , El gobierno de Panamá legalizó el uso medicinal y terapéutico del cannabis Full text, Infobae, 14 October 2021, Accessed on: 22 January 2023.
  114. ↑ , Peru legalises medical marijuana in move spurred by mother's home lab Full text, The Guardian, 20 October 2017, Accessed on: 4 Nov 2017.
  115. ↑ , Medical use of cannabis officially legal in Poland Full text, Radio Poland, 11 February 2017, Accessed on: 4 November 2017.
  116. ↑ , Portugal passes medical cannabis law, opens domestic market Full text, Marijuana Business Daily, 21 June 2018, Accessed on: 24 August 2018.
  117. ↑ , 10 things to know after Rwanda gives the green light for medical marijuana Full text, The New Times, 29 June 2021, Accessed on: 22 January 2023.
  118. ↑
  119. ↑ , Switzerland to legalise medicinal cannabis from Monday Full text, The Local, 28 July 2022, Accessed on: 22 January 2023.
  120. ↑ , Thailand Approves Medical Marijuana In Regional First Full text, HuffPost, 25 December 2018, Accessed on: 20 January 2019.
  121. ↑ , Medicinal cannabis products to be legalised Full text, BBC, 26 July 2018, Accessed on: 28 July 2018.
  122. ↑ Sativex (delta-9-tetrahydrocannabinol and cannabidiol) Full text, GW Pharmaceuticals, Accessed on: 5 November 2017.
  123. ↑
  124. ↑ Sapra, Bani, Canada becomes second nation in the world to legalize marijuana Full text, CNN, 20 June 2018, Accessed on: 3 July 2018.
  125. ↑ , Weed Is Now Legal in Thailand. How Long Will the High Times Last? Full text, The New York Times, 10 November 2022, Accessed on: 22 January 2023.
  126. ↑ , Legal Pot In Mexico: Everything You Need to Know Full text, , 14 September 2017, Accessed on: 5 November 2017.
  127. ↑ , Legalizing Cannabis Violates the UN Drug Control Treaties, But Progressive Countries Like Canada Have Options, Ottawa Law Review, Vol. 49(Issue: 2), Full text, Accessed on: 8 January 2021.
  128. ↑ Classification of controlled drugs Full text, European Monitoring Centre for Drugs and Drug Addiction, Accessed on: 7 January 2021.
  129. ↑ , Report of the International Narcotics Control Board on the Availability of Internationally Controlled Drugs: Ensuring Adequate Access for Medical and Scientific Purposes. online version, Vienna:United Nations, 2010,
  130. ↑ Obligations arising from human rights standards: Access to controlled substances as medicines Full text, International Centre on Human Rights and Drug Policy (University of Essex), United Nations Development Programme, Joint United Nations Programme on HIV/AIDS, Office of the United Nations High Commissioner for Human Rights, World Health Organization, International Guidelines on Human Rights and Drug Policy, 2012, Accessed on: 2024-08-30.
  131. ↑ , The UN removes cannabis from a list of the most dangerous substances Full text, CNN, 2 December 2020, Accessed on: 7 January 2021.
  132. ↑ , U.N. Reclassifies Cannabis as a Less Dangerous Drug Full text, The New York Times, 2 December 2020, Accessed on: 7 January 2021.
  133. ↑ , WHO recommends rescheduling of cannabis Full text, European Monitoring Centre for Drugs and Drug Addiction, 25 March 2019, Accessed on: 7 January 2021.
  134. ↑ , WHO Recommends Rescheduling Cannabis in International Law for First Time in History Full text, Newsweek, 8 February 2019, Accessed on: 7 January 2021.
  135. ↑ , Jeff Sessions personally asked Congress to let him prosecute medical-marijuana providers Full text, , 13 June 2017, Accessed on: 9 July 2017.
  136. ↑ , "New" Pot Pill For Chemo Patients Full text, CBS News, 16 May 2006, Accessed on: 26 July 2017.
  137. ↑ Final Rule: Placement of FDA-Approved Products of Oral Solutions Containing Dronabinol [(-)-delta-9-trans-tetrahydrocannabinol (delta-9-THC)] in Schedule II Full text, U.S. Department of Justice, Accessed on: 2 February 2018.
  138. ↑ Timothy B. Wheeler, Medical marijuana fees stir debate in Maryland Full text, , 11 October 2014, Accessed on: 12 October 2014.
  139. ↑ Blackwell, Tom, The pot vending machine's first foreign market? Canada, of course, "a seed for the rest of the world" Full text, , 16 October 2013, Accessed on: 4 December 2013.
  140. ↑ Uber-For-Weed Startup Meadow Lights Up In San Francisco Full text, , AOL, 14 October 2014, Accessed on: 22 January 2016.
  141. ↑ The UK is the world's largest producer of legal Cannabis, UN body finds Full text, The Independent, 2018-03-07, Accessed on: 2020-12-07.
  142. ↑ The Medical Marijuana Debate Full text, Compliance Corner, Wolters Kluwer Financial Services, 10 February 2015, Accessed on: 26 February 2015.
  143. ↑ Court: Employer can't block workers' comp for medical marijuana Full text, NM Political Report, 29 June 2015, Accessed on: 30 June 2015.
  144. ↑ Resolution on Medical Marijuana Full text, druglibrary.org, Accessed on: 30 July 2017.
  145. ↑ House of Delegates 2017, Resolution: A8 Full text, amsa.org, American Medical Student Association, Accessed on: 30 July 2017.
  146. ↑ Medical Marijuana (Cannabis) FAQs Full text, National Multiple Sclerosis Society, Accessed on: 30 July 2017.
  147. ↑
  148. ↑ Medical Marijuana Use and Research Full text, maps.org, Leukemia & Lymphoma Society, Accessed on: 30 July 2017.
  149. ↑ Position Statement on Marijuana as Medicine Full text, American Psychiatric Association, Accessed on: 30 July 2017.
  150. ↑
  151. ↑
  152. ↑
  153. ↑ American Heart Association, Medical Marijuana, Recreational Cannabis, and Cardiovascular Health, Circulation, Vol. 142(Issue: 10), pp. e131–52, DOI: 10.1161/CIR.0000000000000883, PMID: 32752884,
  154. ↑ Marijuana and Cancer Full text, American Cancer Society, Accessed on: 12 July 2017.
  155. ↑ , Marijuana research: Overcoming the barriers Full text, American Psychological Association, 14 September 2017, Accessed on: 9 October 2017.
  156. ↑ Cannabis, cannabinoids and cancer – the evidence so far Full text, Arney, Kat, , Cancer Research UK, 25 July 2012,
  157. ↑ World Health Organization, List of Proposed INNs No. 51, WHO Chronicle, Vol. 38(Issue: 2), Full text,
  158. ↑ World Health Organization, List of Recommended INNs No. 24, WHO Chronicle, Vol. 38(Issue: 6), Full text,
  159. ↑ Riboulet-Zemouli, Kenzi, 'Cannabis' ontologies I: Conceptual issues with Cannabis and cannabinoids terminology, Drug Science, Policy and Law, Vol. 6 pp. 205032452094579, DOI: 10.1177/2050324520945797, Full text,
  160. ↑ World Health Organization, List of Recommended INNs No. 77, WHO Drug Information, Vol. 31(Issue: 1), Full text,
  161. ↑ , Medical use of cannabis and cannabinoids containing products – Regulations in Europe and North America, European Journal of Internal Medicine, Vol. 49 pp. 2–6, DOI: 10.1016/j.ejim.2018.01.001, PMID: 29329891,
  162. ↑ Produkt – FASS Allmänhet Full text, , Accessed on: 26 December 2013.
  163. ↑ Cannabis Unmasked: What it is and why it does what it does Full text, Youssef, Farid F., , June 2010, Accessed on: 11 May 2021.
  164. ↑ , Cannabis-Based Products for Chronic Pain: A Systematic Review, Ann Intern Med, 2022, Vol. 175(Issue: 8), pp. 1143–1153, DOI: 10.7326/M21-4520, PMID: 35667066, Full text, Accessed on: 19 February 2023.


Further reading[edit | edit source]

, 

 The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. online version, 
  
 National Academies of Sciences, Engineering, and Medicine: The National Academies Press, 
  
  
  
 ISBN 978-0-309-45304-2, 
 DOI: 10.17226/24625, 
  
 Accessed: 7 February 2017.
open access

External links[edit | edit source]

, links to websites about medical cannabis


WikiMD
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.com/w/index.php?title=Medical_cannabis&oldid=6181846#Modern"

Contributors: Prab R. Tumpati, MD